Sweden · Delayed Price · Currency is SEK AlzeCure Pharma AB Company Description
AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system.
The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms.
Its products pipeline includes ACD856 for the treatment of Alzheimer’s disease, sleep disorders, depression, traumatic brain injuries, and Parkinson’s disease, which is in phase I clinical trial; ACD857, ACD679, and ACD680 that are in preclinical trial for the treatment of Alzheimer’s disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain indications; and ACD137, negative allosteric modulator (NAM) of TrkA receptors for osteoarthritic pain indications.
The company was founded in 2012 and is based in Huddinge, Sweden.
| Country | Sweden |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Martin Jönsson |
Contact Details
Address: Hälsovägen 7 Huddinge, 141 57 Sweden | |
| Phone | 46 7 63 16 24 77 |
| Website | alzecurepharma.se |
Stock Details
| Ticker Symbol | ALZCUR |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0010133785 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Martin Jönsson | Chief Executive Officer |
| Birgitta Lundvik | Chief Financial Officer |
| Johan Sandin | Chief Scientific Officer |
| Pontus Forsell | Head of Research and Discovery |
| Dr. Marta Segerdahl Storck M.D., Ph.D. | Chief Medical Officer |
| Dr. Cecilia Wadell MSc Pharm, Ph.D. | Head of Development |